Safety and Efficacy Study of DCVax-Direct in Solid Tumors

Summary

The study comprises a Phase I component during which the optimal dose of DCVax-Direct for the treatment of solid tissue tumors will be identified, followed by a Phase II component to determine if the injection of DCVax-Direct into selected solid tissue tumors has the ability to reduce tumor growth.

Timeline

Start

2013-06

Primary completion

2016-12

Completion

—

Drugs

Indications